Norðurslóð 4 ehf.: Ársreikningur 2024

Seeking Alpha / 43 minutes from now 1 Views

Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025

3 hours from now
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

3 hours from now
Artiva Biotherapeutics to Present Longer-term Phase 1/2 Data for AlloNK® in Combination with Rituximab in Patients with B-cell-Non-Hodgkin Lymphoma at the ASGCT 28th Annual Meeting

3 hours from now
Blade Air Mobility Announces Date for First Quarter Ending March 31, 2025 Earnings Release Conference Call

3 hours from now
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

3 hours from now